Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: Evidences from in vitro and in vivo studies

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 7105-7113

  Santos, Juliana I ^a,b   Teixeira, Ana L ^a,b   Dias, Francisca ^a,b   Maurício, Joaquina ^a   Lobo, Francisco ^a   Morais, António ^a   Medeiros, Rui ^a,b,c,d  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c Portuguese League Against Cancer (Norte)   (Portugal)

^d UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

CRPC development; miR 221; miR 7; Peripheral whole blood microRNAs; Prostate cancer

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; MICRORNA; MICRORNA 221; MICRORNA 222; MICRORNA 7; UNCLASSIFIED DRUG;

AGED; ANTIANDROGEN THERAPY; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; GLEASON SCORE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LNCAP CELL LINE; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

AGED; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84905044659     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1918-9     Document Type: Article

References (58)

1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079-92.
2. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572-83.
3. Heidegger I, Massoner P, Eder IE, Pircher A, Pichler R, Aigner F, et al. Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. J Steroid BiochemMol Biol. 2013;138:248-56.
4. Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15:3251-5.
5. Aggarwal R, Ryan CJ. Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist. 2011;16:264-75.
6. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34-45. (Pubitemid 33741879)
7. Hessvik NP, Sandvig K, Llorente A: Exosomal miRNAs as biomarkers for prostate cancer. Frontiers in genetics 2013;4
8. Zhu KC, Lu JJ, Xu XL, Sun JM. MicroRNAs in androgen-dependent PCA. Front Biosci. 2013;18:748-55.
9. Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009;69:3356-63.
10. Szczyrba J, Loprich E, Wach S, Jung V, Unteregger G, Barth S, et al. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res: MCR. 2010;8:529-38.
11. Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate. 2012;72:1469-77.
12. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27kip1. J Biol Chem. 2007;282:23716-24. (Pubitemid 47311902)
13. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR, et al. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells. 2009;27:1712-21.
14. Cho WCS. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42:1273-81.
15. Shah MY, Calin GA. MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. Genome Med. 2011;3:56.
16. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, et al. TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci Signal. 2011;4:ra41.
17. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T, Newman RJ, Yue P, Bourgon R, Modrusan Z, Stern HM, Warming S, de Sauvage FJ, Amler L, Yeh RF, Dornan D: miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Science signaling 2011;4:pt5
18. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA. Farace MG: miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27kip1. J Biol Chem. 2007;282:23716-24. (Pubitemid 47311902)
19. Hassan O, Ahmad A, Sethi S, Sarkar FH. Recent updates on the role of microRNAs in prostate cancer. J Hematol Oncol. 2012;5:9.
20. Zhang C, Zhang J, Hao J, Shi Z, Wang Y, Han L, et al. High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med. 2012;10:119.
21. Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, Kao YR, et al. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res. 2010;70:8822-31.
22. Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocrine-Related Cancer. 2013;20:R83-99.
23. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11-22.
24. Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, et al. Transatlantic Prostate G: molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer. 2010;102:678-84.
25. Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, et al. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mtor kinase in endometrioid endometrial carcinoma. BMC Cancer. 2012;12:369.
26. Watanabe R, Wei L, Huang J. mTOR signaling, function, novel inhibitors, and therapeutic targets. J Nucl Med: Off Publ Soc Nucl Med. 2011;52:497-500.
27. Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One. 2011;6:e25787.
28. Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K, et al. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol. 2011;38:1093-101.
29. Williams LV, Veliceasa D, Vinokour E, Volpert OV. miR-200b inhibits prostate cancer EMT, growth and metastasis. PLoS One. 2013;8:e83991.
30. Teixeira AL, Ribeiro R, Morais A, Lobo F, Fraga A, Pina F, et al. Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. Pharmacogenomics J. 2009;9:341-6.
31. Gan Y, Shi C, Inge L, Hibner M, Balducci J, Huang Y. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene. 2010;29:4947-58.
32. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgenin-dependence in human prostate cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2002;8:3438-44. (Pubitemid 35340719)
33. Traish AM, Morgentaler A. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer. 2009;101:1949-56.
34. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem. 2004;279:7119-30. (Pubitemid 38248859)
35. Zhang J, Zhao H, Gao Y, Zhang W. Secretory miRNArnas as novel cancer biomarkers. Biochim Biophys Acta. 1826;2012:32-43.
36. Calin GA, Croce CM. MicroRNArna signatures in human cancers. Nat Rev Cancer. 2006;6:857-66.
37. Cho WC. OncomiRrs: tThe discovery and progress of microRNArnas in cancers. Mol Cancer. 2007;6:60.
38. Rossbach M. Small non-coding rnas RNAs as novel therapeutics. Curr Mol Med. 2010;10:361-8.
39. Watahiki A, Wang Y, Morris J, Dennis K, O'Dwyer HM, Gleave M, et al. MicroRNArnas associated with metastatic prostate cancer. PLoS One. 2011;6:e24950.
40. Nana-Sinkam SP, Croce CM. MicroRNArnas as therapeutic targets in cancer. Transl Res. 2011;157:216-25.
41. Staszel T, Zapala B, Polus A, Sadakierska-Chudy A, Kiec-Wilk B, Stepien E, et al. Role of microRNArnas in endothelial cell pathophysiology. Pol Arch Med Wewn. 2011;121:361-6.
42. Carlsson J, Helenius G, Karlsson MG, Andren O, Klinga-Levan K, Olsson B. Differences in microRNArna expression during tumor development in the transition and peripheral zones of the prostate. BMC Cancer. 2013;13:362.
43. Lorenzen JM, Thum T. Circulating and urinary microRNArnas in kidney disease. Clin J Am Soc Nephrol: CJASN. 2012;7:1528-33.
44. Walter BA, Valera VA, Pinto PA, Merino MJ. Comprehensive microRNArna profiling of prostate cancer. J Cancer. 2013;4:350-7.
45. Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, et al. Circulating microRNArnas: nNew biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012;41:1897-912.
46. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, et al. Circulating miRNArnas are correlated with tumor progression in prostate cancer. Int J Cancer J Int Cancer. 2011;128:608-16.
47. Lewis H, Lance R, Troyer D, Beydoun H, Hadley M, Orians J, Benzine T, Madric K, Semmes OJ, Drake R, Esquela-Kerscher A: mMiRr-888 is an expressed prostatic secretions-derived microRNArna that promotes prostate cell growth and migration. Cell cycle 2013;13.
48. Jung HM, Phillips BL, Patel RS, Cohen DM, Jakymiw A, Kong WW, et al. Keratinization-associated miRr-7 and miRr-21 regulate tumor suppressor reversion-inducing cysteine-rich protein with kazal motifs (RECkreck) in oral cancer. J Biol Chem. 2012;287:29261-72.
49. Rai K, Takigawa N, Ito S, Kashihara H, Ichihara E, Yasuda T, et al. Liposomal delivery of microRNArna-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther. 2011;10:1720-7.
50. Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y, et al. Identification of miRr-7 as an oncogene in renal cell carcinoma. J Mol Histol. 2013;44:669-77.
51. Teixeira AL, Gomes M, Medeiros R. Egfr signaling pathway and related-miRNArnas in age-related diseases: tThe example of miRr-221 and miRr-222. Front Genet. 2012;3:286.
52. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, et al. MicroRNArna-221/222 confers tamoxifen resistance in breast cancer by targeting p27kip1. J Biol Chem. 2008;283:29897-903.
53. Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, et al. Circulating miRr-221 directly amplified fromplasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010;25:1674-80.
54. Li W, Guo F, Wang P, Hong S, Zhang C. mMiRr-221/222 confers radioresistance in glioblastoma cells through activating Aakt independent of PTENpten status. Curr Mol Med. 2014;14:185-95.
55. Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, et al. MicroRNArna-221 and microRNArna-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTENpten. BMC Cancer. 2010;10:367.
56. Teixeira AL, Ferreira M, Silva J, Gomes M, Dias F, Santos JI, Mauricio J, Lobo F, Medeiros R: Higher circulating expression levels of miRr-221 associated with poor overall survival in renal cell carcinoma patients. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2013.
57. Dias F, Teixeira AL, Santos JI, Gomes M, Nogueira A, Assis J, et al. Renal cell carcinoma development and miRNArnas: Aa possible link to the EGFRegfr pathway. Pharmacogenomics. 2013;14:1793-803.
58. Di Lorenzo G, Autorino R, De Laurentiis M, Cindolo L, D'Armiento M, Bianco AR, et al. HERer-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori. 2004;90:163-70. (Pubitemid 38745602)